Cataplexy plus presence of HLA-DQB1*0602 allele can predict Hypocretin-1 deficiency

Currently, narcolepsy patients are treated with stimulants and other drugs for cataplexy.[1] However, emerging therapies focus on hypocretin-1 "replacement" and immunotherapy.[2] Unfortunately, the hypocretin-1 levels in CSF analysis depend on a lumbar puncture and radioimmunoassay, which are not available for the most part in sleep centers. Thus/Therefore, we studied the areas under the ROC curve of clinical or/and electrophysiology methods to predict Hypocretin-1 deficiency.

http://ift.tt/2ApcNXk